Neoadjuvant pembrolizumab appeared to offer more favorable results among both cisplatin-eligible and cisplatin-ineligible patients. A study compared response to neoadjuvant pembrolizumab vs chemo prior to surgery for muscle-invasive bladder cancer (MIBC).